Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01609062 · ClinicalTrials.gov registry record · Phase 2
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
A Phase 2 study, sponsored by BioMarin Pharmaceutical.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01609062 is a Phase 2 study that was terminated before completion, run by BioMarin Pharmaceutical. The registered enrollment target is 25 participants.
The verdict
NCT01609062, a Phase 2 study, was terminated before completion, sponsored by BioMarin Pharmaceutical.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks. Secondary objectives were to investigate the effect of the two doses on exercise capacity for up to 196 weeks. In addition, the pharmacokinetic (PK) parameters of both doses of BMN 110 was assessed.
Interventions
- DRUG BMN 110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01609062
The ClinicalTrials.gov registry entry for NCT01609062 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMN 110 is the first listed.
NCT01609062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01609062 about?
NCT01609062 is a clinical study titled "Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome". The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks. Secondary objectives were to investigate the effect of the two doses on exercise capacity for up to 196 weeks. In addition, the ...
What is the current status of trial NCT01609062?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2012-04. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01609062?
The interventions under investigation include: BMN 110 (DRUG).
Who is sponsoring clinical trial NCT01609062?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.